EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Epitope identification for p53R273C mutant

Jian Zhang iD, Minglu Liu, Yin Chen, Zishan Zhou, Ping Wang, Yang Yu, Shunchang Jiao

Immunity, Inflammation and Disease · 2023

DOI: 10.1002/iid3.752 ↗

At a glance

Journal article in Immunity, Inflammation and Disease, 2023. Written by Jian Zhang and 6 co-authors. Institution: School of Medicine, Nankai University, Tianjin, China. Major MEDLINE topics: Antigens, Neoplasm, Neoplasms, Tumor Suppressor Protein p53. 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

With the rise of immunotherapy based on cancer neoantigen, identification of neoepitopes has become an urgent problem to be solved. The TP53 R273C mutation is one of the hotspot mutations of TP53, however, the immunogenicity of this mutation is not yet clear. The aim of this study is to identify potential epitopes for p53R273C mutant.

Methods

In this study, bioinformatic methods, peptide exchange assay, and peptide‐immunized human leukocyte antigen (HLA) transgenic mouse model were used to explore the immunogenicity of this mutation.

Results

Peptides with higher affinity to common HLA‐A alleles (A*11:01, A*02:01) were discovered by computational prediction. All the 8–11 mer peptides contain the mutation site were synthesized and soluble peptides were used in the peptide exchange assay. However, the exchange efficiencies of these predicted peptides to HLAs were lower. Fortunately, other peptides with higher exchange efficiency were discovered. Then, the immunogenicity of these peptides was validated with the HLA‐A2 transgenic mice model.

Conclusion

We identified three potential neoepitopes of p53 R273C for HLA‐A*02:01, one potential neoepitope for HLA‐A*11:01 and no neoepitope for HLA‐A*24:02.

Subjects

MeSH terms (MEDLINE)

Antigens, NeoplasmNeoplasmsTumor Suppressor Protein p53AnimalsHumansMiceEpitopesHLA AntigensMice, TransgenicPeptides

Author keywords

TP53 R273C mutationimmunogenicityimmunotherapyneoantigen

Substances

Antigens, NeoplasmEpitopesHLA AntigensPeptidesTumor Suppressor Protein p53

Authors and institutions

  • School of Medicine, Nankai University, Tianjin, China.
  • Department of Oncology, Oncology Laboratory, Chinese PLA General Hospital, Beijing, China.
  • Research and Development Department, Beijing DCTY Biotech Co., Ltd., Beijing, People's Republic of China.

ORCID profiles: Jian Zhang

Funding

  • National Natural Science Foundation of China

Cite

APA

Zhang, J., Liu, M., Chen, Y., Zhou, Z., Wang, P., Yu, Y., & Jiao, S. (2023). Epitope identification for p53R273C mutant. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.752

Vancouver

Zhang J, Liu M, Chen Y, Zhou Z, Wang P, Yu Y, et al. Epitope identification for p53R273C mutant. Immunity, Inflammation and Disease. 2023. doi:10.1002/iid3.752

BibTeX
@article{Zhang2023,
  author = {Zhang, Jian and Liu, Minglu and Chen, Yin and Zhou, Zishan and Wang, Ping and Yu, Yang and Jiao, Shunchang},
  title = {Epitope identification for p53R273C mutant},
  journal = {Immunity, Inflammation and Disease},
  year = {2023},
  doi = {10.1002/iid3.752}
}
Start for free →